Paper Title
Studies on APO Lipoproteins (Apo A& Apo B) and Lipoprotein (A) along with Lipid Profile in Type II Diabetes Mellitus and in Patients with Metabolic Syndrome

Patients with type 2 diabetes mellitus or the metabolic syndrome have a unique dyslipidemia characterized by hypertriglyceridemia; elevated blood levels of apolipoprotein B; small, dense low-density lipoprotein (LDL) cholesterol; and low levels of high-density lipoprotein (HDL) cholesterol, in particular HDL2-C. Treatment of the dyslipidemia associated with these disorders should focus on correcting the abnormal lipoprotein levels as well as LDL and HDL heterogeneity. Statins and fibrates are useful for treating elevated LDL in patients with and without diabetes or the metabolic syndrome. There are very less research on Apolipoprotein A and Apolipoprotein B, Lipoprotein (a) in India, in comparison to foreign countries. So this study is aimed to evaluate Apo lipoproteins (Apo A& Apo B) and Lipoprotein (a) levels along with Lipid profile in Type II Diabetes Mellitus and in patients with Metabolic Syndrome which can be correlated with the risk of Cardiovascular disease.In our present study 88 males out of 133 and 45 females out of 133 were found to be dyslipidemia. The mean levels of Apo lipoproteins (Apo A& Apo B) and Lipoprotein (a) were increased in Metabolic syndrome (153.67, 131.15 and 27.18) respectively compared to in Type II Diabetes were (127.11, 123.71 and 21.21) respectively. It was significant with ApoA1 (P-Vale =0.006). No significant with lipid profile. Conclusion: TheApo lipoprotein A1, Apolipoprotein B and Lipoprotein (a) can be important marker for the risk developing of heart disease. Statistical relationships between LDL and HDL and their respective Apo lipoproteins, apo B and apo A-1, in diabetic, non-diabetic and healthy subjects can be established. Lp(a) levels is reliable predictor of CAD severity in type II diabetic patients Keywords - Lipid profile,Type II Diabetes Mellitus, Apo lipoproteins (Apo A& Apo B), Lipoprotein (a) and Metabolic Syndrome.